UK-based Cellnovo, developer of a mobile diabetes management system, received £30 million ($48.4 million) in a Series B financing round, led by Edmond de Rothschild Investment Partners (EdRIP) to fund commercialization of their system and expansion into new markets. It integrates a micropump, a blood glucose meter, a mobile handset that records all data and online access/management. It is also EdRIP’s first investment in a UK firm. Competitors are substantial: Johnson & Johnson LifeScan, Medtronic and Insulet OmniPod. MedCityNews Cellnovo press release.
WellDoc, last in the news with FDA approval for Diabetes Manager and distribution via AT&T ForHealth [TA 15 Oct], and with EHR integration [TA 14 Dec], acquired Oncology Care Home Health to accelerate the development of its next device for oncology management. Terms were not disclosed but the company will be operated as an independent subsidiary for education and consulting for home health providers’ specialized oncology care programs. WellDoc and Oncology Care will also integrate intellectual property and information systems. Release.